Antibodies for HIV prevention: the path forward

Rather than shirk from this challenge, we must leapfrog to a new paradigm for how mAbs are conceived, developed and delivered, guided by the following four principles (Table 1): Table 1 Key stakeholders and core principles for advancing mAbs access Discovery Clinical development Manufacturing and supply Registration/policy guidance Introduction Scale up Key stakeholders Communities and civil society √ √ √ √ √ √ Funders √ √ √ √ √ √ Academia √ √ Innovator (bio)industry √ √ √ √ Biosimilar industry √ √ Product development partnerships √ √ Social and implementation scientists √ √ √ √ Procurers √ WHO √ National authorities and programmes √ √ √ End users √ √ √ √ Implementers √ Recommendations Communities at the core √ √ √ √ √ √ Access-oriented research agenda—with conditions √ √ √ Business model innovation √ √ √ Embrace current tools while expanding options √ √ √ √ √ Place communities at the core: A truly person-centred approach, with a justice and equity lens, is needed to remove systemic barriers and address asymmetries in access to mAbs [ 4]. Novel business models are needed to harness market forces towards public good, enabled by voluntary licensing strategies, technology transfer, access to low-cost reference products and waivers of additional clinical trial requirements, where appropriate [ 10]. ACKNOWLEDGEMENTS The authors would like to thank the Global HIV Vaccine Enterprise at IAS—the International AIDS Society—for hosting the dialogue that formed the basis of this Viewpoint at the 24th Annual International AIDS Conference in Montreal.